Structure Therapeutics (GPCR) Corporate presentation summary

Mission and strategic vision

• Focus on making medicines more accessible globally, targeting significant unmet needs in obesity and related metabolic diseases.

• Platform centers on oral small molecule therapeutics for chronic conditions.

Market opportunity and growth

• Over 1 billion people worldwide are affected by obesity, with 3 billion overweight or obese.

• Oral GLP-1 therapies are rapidly expanding the obesity market, with >1.2M patients on therapy in Q1 2026.

• By 2035, orals could represent 25-50% of the obesity treatment market.

Pipeline and clinical development

• Aleniglipron, a selective oral GLP-1 receptor agonist, is Phase 3 ready, showing up to 16.3% body weight loss at 44 weeks.

• ACCG-2671, a first-in-class oral DACRA, is in Phase 1 with promising preclinical efficacy and safety.

• Fixed dose GLP-1R + Amylin combination achieved proof of concept in obese NHPs; clinical study planned for Q4 2026.

• Multiple ongoing and planned studies, including for T2DM, body composition, and switch from injectables.